Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 126-Z:2 · Availability of Investigational Drugs, Biologics, or Devices; Costs; Coverage

Title
X: PUBLIC HEALTH
Chapter
126-Z · RIGHT TO TRY ACT
Status
current
Official source linked
Yes
Official source Copy section link

126-Z:2 Availability of Investigational Drugs, Biologics, or Devices; Costs; Coverage. –

Copy link
I.

A manufacturer of an investigational drug, biologic, or device may make available an investigational drug, biologic, or device to eligible patients pursuant to this chapter. A manufacturer may:

Copy link
(a)

Provide an investigational drug, biologic, or device to an eligible patient without receiving compensation.

Copy link
(b)

Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biologic, or device.

Copy link
(c)

Require an eligible patient to participate in data collection relating to the use of the investigational drug, biologic, or device.

Copy link
II.

This chapter shall not require a health care insurer or any state agency to provide coverage for the cost of any investigational drug, biologic, or device.

Copy link
III.

Nothing in this chapter shall require the manufacturer of an investigational drug, biologic, or device to include an eligible patient in a particular clinical trial or study.

Copy link
IV.

Nothing in this chapter shall require a health care provider, health care facility, or the manufacturer of an investigational drug, biological product, or device, to make an experimental treatment available to an eligible patient. Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025. 2025, 304:6, eff. Jan. 1, 2026.

Copy link

Source note

Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025. 2025, 304:6, eff. Jan. 1, 2026.

Source history

  • 2016, 206:2, eff. June 6, 2016
  • 2024, 124:1, eff. Jan. 1, 2025
  • 2025, 304:6, eff. Jan. 1, 2026

Related materials

Bill relationships

  • 2026 HB1292 amend · effective 2027-01-01

    l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati

  • 2026 HB1292-FN amend · effective 2027-01-01

    l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati

  • 2026 HB1809 reference · effective 2030-11-01

    ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat

  • 2026 HB1809-FN reference · effective 2030-11-01

    ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat

  • 2026 SB504 reference · effective 2027-01-01

    nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t

  • 2026 SB504-FN reference · effective 2027-01-01

    nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t

  • 2026 SB616 amend · effective 2027-07-01

    r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to

  • 2026 SB616-FN amend · effective 2027-07-01

    r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to